Antiretroviral resistance testing in HIV infected patients improves health and saves costs

January 24, 2007

During HIV treatment resistance mutations of the virus to antiretroviral drugs may occur and the treatment regimen become less effective. In the present study the authors compared the cost-effectiveness of genotypic antiretroviral resistance testing versus expert opinion for treatment optimization in HIV infected patients with treatment failure.

The study is based on data from the Swiss HIV Cohort Study (www.shcs.ch), which is one of the largest cohort studies on HIV disease including patients from all University Clinics and two state hospitals in Switzerland. In this study, both health care costs and productivity costs, i.e. costs due to absence from work because of ill-health, were included in the analysis. Using most recent scientific methods, the authors could show that antiretroviral resistance testing not only increases life expectancy and quality-of-life, but also results in cost savings to society.

"This is the first study that shows that resistance testing not only improves the health of the patients but is also beneficial to the society at large when job productivity changes are considered," said Pedram Sendi, first author and principal investigator, from the Clinic of Infectious Diseases & Hospital Epidemiology of the Basel University Hospital. "We are convinced that our study will be noticed in many countries as it also documents the clinical benefit of antiretroviral resistance testing," comment Manuel Battegay from the Basel University Hospital and Huldrych Günthard from the Zurich University Hospital, co-principals of this cost-effectiveness study.

In times of increasing pressures to contain health care costs cost-effectiveness analyses are an important source of information to evaluate whether health interventions represent "value for money." This may help to prioritize resource allocation in health care by finding those health technologies that offer the most health outcomes for the resources invested. To date the Swiss HIV Cohort Study has conducted several cost-effectiveness analyses and has contributed to a better understanding of important cost-effectiveness issues in HIV disease.

Citation: Sendi P, Günthard HF, Simcock M, Ledergerber B, Schüpbach J, et al (2007) Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure. PLoS ONE 2(1): e173. doi:10.1371/journal.pone.0000173 (dx.doi.org/10.1371/journal.pone.0000173)

Source: Public Library of Science

Explore further: River prawns stop disease spread in West Africa

Related Stories

River prawns stop disease spread in West Africa

August 25, 2015

The Diama Dam that spans between Senegal and Mauritania in West Africa was intended to improve crop irrigation when it was built in 1986. But while preventing saltwater intrusion, the dam also altered the region's ecology, ...

We must defend science if we want a prosperous future

March 3, 2015

Today's Australians are, by far, the best educated cohort in our history –- on paper, anyway -– but this is not reflected in the quality of our political discourse. We appear to be lacking in courage, judgement, capacity ...

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

(PhysOrg.com) -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.